Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PA-12
- Development stage
- Unknown
- Lead developer
- Lincoln Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
PA-12 is a sustained-release oral tablet formulation of paracetamol (acetaminophen) developed by Lincoln Pharmaceuticals. Utilizing a New Drug Delivery System (NDDS), the product is designed as a 'programmed release' tablet containing a total dose of 1000 mg, partitioned into a 300 mg immediate-release component and a 700 mg sustained-release component. This dual-release profile is intended to provide rapid onset of action followed by prolonged therapeutic levels, allowing for twice-daily dosing. PA-12 acts as an analgesic and antipyretic by centrally blocking the release of chemical messengers (prostaglandins) that cause pain and fever, acting on pain pathways and heat-regulatory centers in the brain. It is approved and marketed in India for the treatment of fever and various pain conditions, including headache, body ache, toothache, and period pain.
- Brand names
- PA-12PA12PA 12
- Other names
- Paracetamol 1000mg Programmed Release TabletParacetamol1000mg Programmed Release TabletParacetamol-1000mg Programmed Release TabletAcetaminophen 1000mg Programmed Release TabletAcetaminophen1000mg Programmed Release TabletAcetaminophen-1000mg Programmed Release Tablet
Beyond the preview
Go deeper on PA-12.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PA-12.